- Home
- PHGE vs TNON Comparison
PHGE vs TNON Comparison
Compare PHGE & TNON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHGE
- TNON
- Stock Information
- Founded
- PHGE 2015
- TNON 2012
- Country
- PHGE Israel
- TNON United States
- Employees
- PHGE N/A
- TNON N/A
- Industry
- PHGE Biotechnology: Pharmaceutical Preparations
- TNON Medical Specialities
- Sector
- PHGE Health Care
- TNON Health Care
- Exchange
- PHGE Nasdaq
- TNON Nasdaq
- Market Cap
- PHGE 12.6M
- TNON 11.5M
- IPO Year
- PHGE N/A
- TNON 2022
- Fundamental
- Price
- PHGE $0.55
- TNON $1.16
- Analyst Decision
- PHGE Strong Buy
- TNON Strong Buy
- Analyst Count
- PHGE 1
- TNON 2
- Target Price
- PHGE $15.00
- TNON $5.50
- AVG Volume (30 Days)
- PHGE 292.1K
- TNON 159.0K
- Earning Date
- PHGE 11-13-2025
- TNON 11-12-2025
- Dividend Yield
- PHGE N/A
- TNON N/A
- EPS Growth
- PHGE N/A
- TNON N/A
- EPS
- PHGE N/A
- TNON N/A
- Revenue
- PHGE N/A
- TNON $2,947,000.00
- Revenue This Year
- PHGE N/A
- TNON $43.52
- Revenue Next Year
- PHGE N/A
- TNON $82.14
- P/E Ratio
- PHGE N/A
- TNON N/A
- Revenue Growth
- PHGE N/A
- TNON N/A
- 52 Week Low
- PHGE $0.34
- TNON $0.85
- 52 Week High
- PHGE $1.16
- TNON $5.85
- Technical
- Relative Strength Index (RSI)
- PHGE 56.74
- TNON 43.68
- Support Level
- PHGE $0.50
- TNON $1.16
- Resistance Level
- PHGE $0.54
- TNON $1.25
- Average True Range (ATR)
- PHGE 0.03
- TNON 0.05
- MACD
- PHGE 0.00
- TNON 0.00
- Stochastic Oscillator
- PHGE 71.42
- TNON 13.04
About PHGE BiomX Inc. COmmon Stock
BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).
About TNON Tenon Medical Inc.
Tenon Medical Inc is a medical device company that has developed a novel, minimally invasive approach to the sacroiliac joint (the SI Joint) using a single, robust, titanium implant for the treatment of the common types of SI Joint disorders that cause lower back pain. The Company is focused on three commercial opportunities; Primary SI Joint procedures, Revision procedures of failed SI Joint implants, and SI Joint fusion adjunct to a spine fusion construct. The company derives the majority of its revenue from sales of The Catamaran System to a limited number of clinicians.